Computational Chemistry Intern (Summer 2025)

Genesis Therapeutics is bringing together a world-class computational team to build out the industry's fastest and most accurate small molecule property predictions, by combining the power of machine learning and physics-based methods. We are seeking experts skilled in developing and applying simulation methodologies to help drive forward our challenging drug discovery programs.

You will

• Develop and refine advanced simulation methods and models to help solve pressing challenges in our internal drug programs
• Utilize our cluster of 1,000s of GPUs and 10,000s of CPUs for massive experimentation, with an easy-to-use Python API that manages autoscaling, parallelization, and data pipelining behind the scenes
• Work closely with our ML researchers, computational chemists, and medicinal chemists to validate and quickly deploy improvements to our ML/MD platform for our chemists' daily use on our internal drug programs and collaborations
  
  
  
  
  

You are

• A PhD-level researcher with a proven track record of applying or developing simulation methods and models to explore challenging problems related to drug discovery
• Passionate about building methods to solve real problems in active drug discovery programs, and in doing so help to drug the previously undruggable
• A skilled programmer, preferably in Python, such that you can quickly implement your research ideas and analyze their performance across our benchmark suite
  
  
  
  
  

What We Offer

• The opportunity to work on challenging, high impact computational chemistry research that is immediately deployed to accelerate the discovery of new medicines
• A world-class, tight-knit team of good-hearted people across software, machine learning, computational chemistry, medicinal chemistry, and biology
• Competitive salary and equity. Medical, dental, and vision insurance, and a 401(k) program
• One-on-one mentor to help guide your research and act as a point person for questions
  
  
  
  
  

Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.

Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.

The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022, with a $20M upfront payment and a $670M total deal size), and Genentech (signed in 2020).

We raised a $200M series B in August 2023, and have raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.

Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.

Finding the best talent is our top priority at Genesis Therapeutics. If you are interested in potential partnership on recruitment, please reach out to recruiting@genesistherapeutics.ai.